Търсене на изпитвания

AI · Cancer

Намерени 1,993 изпитвания за "Cancer" Стр. 51 от 100

Набира участници Фаза 1

A Phase I Study of AK138D1 in the Treatment of Advanced Solid Tumors

Solid Cancer

This is an open-label, first-in-human, Phase I clinical study aimed at evaluating the safety, tolerability, PK, immunogenicity, and preliminary antitumor efficacy of AK138D1 in subjects being treated for advanced solid tumors.

Начало: 24.02.2025 Край: 30.08.2028 Възраст: 18–75 г. Лечение

Australia Akeso NCT06730386

Набира участници Фаза 3

Lymphocyte-Sparing And Radio-Immunotherapy in Head and Neck Carcinoma

Oropharynx Cancer Larynx Cancer Hypopharynx Cancer Primary Head and Neck Tumor

The aim of this study is to investigate the effect of ATRA (Vesanoid) and the effect of tailored radiotherapy in patients with squamous cell carcinoma of the oropharynx, larynx or hypopharynx.

Начало: 20.02.2025 Край: 01.01.2029 Възраст: от 18 г.

France Centre Leon Berard NCT06706401

Набира участници Фаза 1

A Study to Evaluate the Safety, Tolerability, Pharmacokinetics (PK), and Antitumor Activity of ALK202 in Participants with Advanced Solid Tumors

Advanced Cancer Advanced Solid Tumor

TThis is a first-in-human (FIH), open-label, multicenter dose escalation and expansion study of ALK202. The purpose of this study is to evaluate the safety, tolerability, pharmacokinetics (PK), and antitumor activity of ALK202 as a monotherapy in adult participants with Advanced Solid Tumors. The study will also identify recommended dose(s) for subsequent clinical studies of ALK202.

Начало: 10.02.2025 Край: 01.12.2028 Възраст: 18–75 г. Лечение

Australia, United States Shanghai Allink Biotherapeutics Co., Ltd. NCT06707610

Набира участници Фаза 1/2

A Study to Evaluate the Safety, Tolerability, Drug Levels, and Preliminary Efficacy of BMS-986507 Combinations in Adult Participants With Advanced Solid Tumors

Lung Cancer Breast Cancer

The purpose of this study is to evaluate the safety, tolerability, drug levels, and preliminary efficacy of BMS-986507 combinations in adult participants with advanced solid tumors.

Начало: 04.02.2025 Край: 26.02.2031 Възраст: от 18 г. Лечение

Australia, Canada, Chile +6 Bristol-Myers Squibb NCT06618287

Набира участници Фаза 2

Dose Individualization of Chemotherapy in Patients With Gastrointestinal Cancers Lacking a Specific Liver Enzyme

Digestive Cancer Colorectal Cancer

The goal of this clinical trial is to establish guidelines for fluoropyrimidine dose reduction according to uracilemia in patients with DPD deficiency in the treatment of digestive cancers. The main question it aims to answer is: \- Which reduction dose of fluoropyrimidine is needed for patient with DPD deficiency? Participants will: * Take the treatment with the reduction of dose stated by the protocol * Visit the clinic once every 2-3 weeks for checkups and tests for collection of adverse events

Начало: 20.01.2025 Край: 01.01.2030 Възраст: от 18 г.

France UNICANCER NCT06475352

Набира участници Фаза 1/2

A Study of BH-30643 in Subjects With Locally Advanced or Metastatic NSCLC Harboring EGFR and/or HER2 Mutations

NSCLC (Advanced Non-small Cell Lung Cancer)

This Phase1/2, open label, multicenter study will assess the safety, tolerability, pharmacokinetics (PK), pharmacodynamics and preliminary anti-tumor activity of BH-30643 in patients with NSCLC having EGFR and/or HER2 mutations. Phase 1 will determine the recommended Phase 2 dose (RP2D) and, if applicable, the maximum tolerated dose (MTD) of BH-30643. Phase 2 will further evaluate the antitumor efficacy and safety in specified cohorts determined by EGFR/HER2 mutation subtypes and/or treatment history at the RP2D, as well as the population PK.

Начало: 09.01.2025 Край: 31.07.2029 Възраст: от 18 г. Лечение

Australia, Canada, Hong Kong +6 BlossomHill Therapeutics NCT06706076

Набира участници

A Long-term Follow-up Study of Subjects Enrolled in Clinical Trials of Cadonilimab (AK104)

Locally Advanced Unresectable or Metastatic Gastric Cancer

This is an observational and non-interventional clinical study that only collects long-term follow-up data of the subjects. As the world's first approved PD-1/CTLA-4 bispecific antibody for marketing, Cadonilimab may confer long-term survival benefits.

Начало: 26.12.2024 Край: 31.12.2040

China Akeso NCT07547787

Набира участници Фаза 1

Phase 1 Study of OP-3136 in Advanced or Metastatic Solid Tumors

Advanced or Metastatic ER+ HER2- Breast Cancer (mBC) Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) Advanced or Metastatic Castration-Resistant Prostate Cancer (mCRPC) Metastatic Breast Cancer +2

This is a first-in-human, open-label, multicenter phase 1 study to evaluate safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD), and preliminary efficacy of OP-3136, a lysine acetyltransferases 6A and 6B (KAT6A/B) inhibitor, as monotherapy and in combination with other anticancer agents in participants with advanced solid tumors. This study consists of 2 parts: a dose escalation part (Part 1) and dose expansion part (Part 2).

Начало: 16.12.2024 Край: 30.08.2027 Възраст: от 18 г. Лечение

Australia, United States Olema Pharmaceuticals, Inc. NCT06784193

Набира участници

Lung Ultrasound in Critically Ill Obstetrics and Gynecological Patients

Obstetric Complication Gynecologic Cancer Lung Diseases Ultrasound

Pulmonary dysfunction aggravates the illness of critically ill obstetrics and gynecological patients. Early identification with bedside technique and prompt management may improve the outcome of critical care in this vulnerable population

Начало: 15.12.2024 Край: 01.05.2026

Egypt Ain Shams University NCT06728709

Набира участници Фаза 3

A Global Phase III Study of Rilvegostomig or Pembrolizumab Plus Chemotherapy for First-Line Treatment of Metastatic Non-squamous NSCLC

Non-squamous Non-small Cell Lung Cancer

The purpose of ARTEMIDE-Lung03 is to evaluate the efficacy and safety of rilvegostomig compared to pembrolizumab, both in combination with platinum-based doublet chemotherapy, as a first-line treatment of patients with non-squamous mNSCLC whose tumors express PD-L1.

Начало: 27.11.2024 Край: 25.03.2030 Възраст: от 18 г. Лечение

Argentina, Australia, Belgium +22 AstraZeneca NCT06627647

Набира участници Фаза 1/2

A Study to Investigate Safety and Effectiveness of BGB-16673 in Combination With Other Agents in Participants With Relapsed or Refractory B-Cell Malignancies

B-cell Malignancy Relapsed Cancer Refractory Cancer B-cell Lymphoma

The purpose of this study is to measure the safety, preliminary antitumor activity, pharmacokinetics, and pharmacodynamics with BGB-16673 in combination with other agents in participants with relapsed or refractory (R/R) B-cell malignancies. This study is structured as a master protocol with separate substudies. This study currently includes four substudies, and more substudies may be added as other combination agents are identified.

Начало: 27.11.2024 Край: 02.12.2029 Възраст: от 18 г. Лечение

Australia, Brazil, China +5 BeOne Medicines NCT06634589

Набира участници

Autologous Testicular Tissue Transplantation

Cancer Sickle Cell Thalassemia Hematologic Diseases

Freezing testicular tissue of prepubertal boys is a method for preserving spermatogonial stem cells in case of imminent gonadotoxic treatment during childhood. In case of total azoospermia or absence of spermatozoa that can be used for intra-cytoplasmic injection (ICSI) in adulthood, the investigators intend to perform the first in men autologous testicular tissue transplantation to restore fertility.

Начало: 22.11.2024 Край: 29.10.2030 Възраст: 18–50 г.

Belgium Universitair Ziekenhuis Brussel NCT05414045

Набира участници Фаза 2

Invert-Prospective Phase II Randomized Trial of Involved Nodal Versus Elective Neck RadioTherapy

Head and Neck Cancer

To determine the risk of solitary elective volume recurrence following involved nodal radiotherapy (INRT) versus elective nodal irradiation (ENI)

Начало: 14.11.2024 Край: 01.07.2028 Възраст: 18–99 г.

United States University of Texas Southwestern Medical Center NCT06477692

Набира участници Фаза 1

Study of IMC-P115C in Advanced PRAME-Positive Cancers

PRAME Positive Cancer HLA-A*02:01-positive

Phase 1 First-in-human study of the safety and efficacy of IMC-P115C as a single agent and in combination with standard of care (SOC) agents in participants with advanced PRAME positive cancers. IMC-P115C is a half-life extended (HLE) ImmTAC targeting PRAME.

Начало: 07.11.2024 Край: 30.08.2029 Възраст: от 18 г. Лечение

Australia, France, Italy +1 Immunocore Ltd NCT07156136

Набира участници Фаза 1/2

A Study to Evaluate the Safety, Tolerability, Pharmacokinetics (PK), and Antitumor Activity of ALK201 in Participants With Advanced Solid Tumors

Advanced Cancer Advanced Solid Tumors

This is a first-in-human (FIH), open-label, multicenter dose escalation and expansion study of ALK201. The purpose of this study is to evaluate the safety, tolerability, pharmacokinetics (PK), and antitumor activity of ALK201 as a monotherapy in adult participants with Advanced Solid Tumors. The study will also identify recommended dose(s) for subsequent clinical studies of ALK201.

Начало: 24.10.2024 Край: 22.04.2028 Възраст: 18–75 г. Лечение

Australia, China Shanghai Allink Biotherapeutics Co., Ltd. NCT06656390

Набира участници

Real-world Evaluation of the HistoSonics Edison System for Treatment of Liver Tumors Across Multidisciplinary Users (BOOMBOX: Master Study)

Liver Neoplasms Primary Liver Cancer Secondary Liver Cancer Tumor Liver +1

The goal of this observational study is to collect information on the use of the HistoSonics Edison System for the treatment of liver tumors. The main aim is to understand how different patient characteristics and procedural characteristics may affect histotripsy success at 36 hours post-histotripsy procedure. Sub-studies to the BOOMBOX: Master Study will investigate specific populations and/or clinical questions with more stringent enrollment criteria, standardized testing criteria, and/or follow-up schedule. Any participant enrolled in the BOOMBOX: Master Study that also qualifies for a sub-study may enroll in the sub-study in parallel; sub-studies will be described in separate sub-study protocols. The BOOMBOX: Master Study will collect information about participants before, during, and after the histotripsy treatment procedure. All participants will be followed per standard clinical follow-up based on each site's clinical practice for up to 5 years after the initial histotripsy procedure or until completion of their follow-up in a sub-study, whichever is longer.

Начало: 14.10.2024 Край: 01.11.2031 Възраст: от 22 г.

United States HistoSonics, Inc. NCT06486454

Набира участници Фаза 1

A Phase 1 Trial of ERX-315 in Participants With Advanced Solid Tumors

Advanced Solid Tumor Metastatic Breast Cancer Metastatic Ovarian Cancer Metastatic Endometrial Cancer +2

This is a Phase 1 study to assess the safety of ERX-315 in patients with advanced solid tumors that have failed approved systemic therapies.

Начало: 14.10.2024 Край: 30.06.2026 Възраст: от 18 г. Лечение

Australia EtiraRx Australia Pty Ltd NCT06533332

Набира участници Фаза 1

Dose-Escalation of MNPR-101-PCTA-177Lu in Solid Tumors

Solid Tumor, Adult Bladder Cancer Urothelial Carcinoma Triple-negative Breast Cancer +5

This is an open-label, uncontrolled, multi-center, phase 1a MNPR-101-PCTA-177Lu dose-escalation study in patients with solid tumor cancers. Patients must have participated in the imaging study MNPR-101-D001 (actively recruiting, diagnostic study of MNPR-101-DFO\*-89Zr). * TITE-BOIN will be used to objectively determine dose increase, no dose change, or dose decrease for each group of two patients. * The treatment period consists of two 12-week cycles. Patients will receive three equal fractions of MNPR-101-PCTA-177Lu with radioactivity ranging from 480-2240 MBq on each of Cycle 1 Day 1, Cycle 1 Day 15, and Cycle 2 Day 1 (12 weeks after Cycle 1 Day 1). * Patients will be followed for 12 weeks after their last dose of MNPR-101-PCTA-177Lu. * Patients will be imaged at specific timepoints during the study.

Начало: 08.10.2024 Край: 01.01.2027 Възраст: от 18 г. Лечение

Australia Monopar Therapeutics NCT06617169

Набира участници Фаза 1/2

Substudy 06C: A Study of Investigational Agents With Pembrolizumab (MK-3475) and Chemotherapy in Participants With First-Line Locally Advanced Unresectable/Metastatic Gastroesophageal Adenocarcinoma (MK-3475-06C/KEYMAKER-U06)

Gastroesophageal Junction Gastroesophageal Adenocarcinoma Esophageal Neoplasms Esophageal Cancer

This is a phase 1/2, multicenter, open-label umbrella platform study that will evaluate the safety and tolerability of investigational agents with pembrolizumab and fluoropyrimidine chemotherapy for the first-line (1L) treatment of participants with locally advanced unresectable or metastatic human epidermal growth factor receptor 2 (HER2)-negative gastric, gastroesophageal junction, or esophageal adenocarcinoma. This substudy will have two phases: a safety lead-in phase and an efficacy phase. The safety lead-in phase will be used to evaluate the safety and tolerability, and to establish a recommended Phase 2 dose (RP2D) for investigational agents in combination with chemotherapy and immunotherapy. There is no formal hypothesis in this study.

Начало: 20.09.2024 Край: 12.09.2029 Възраст: от 18 г.

Brazil, Chile, China +9 Merck Sharp & Dohme LLC NCT06469944

Набира участници Фаза 1

A Study of LY4050784 in Participants With Advanced or Metastatic Solid Tumors

Metastatic Solid Tumor Advanced Solid Tumor Non-small Cell Lung Cancer SMARCA4-Deficient Tumor

The main purpose of this study is to find out whether the study drug, LY4050784, is safe, tolerable and effective in participants alone or in combination with other anticancer agents. In addition, with locally advanced or metastatic solid tumors with a BRG1 (Brahma-related gene 1, also known as SMARCA4) alteration who have previously received, do not qualify for, or are refusing standard of care treatments, or there is no standard therapy available for the disease. The study is conducted in two parts - phase Ia (dose-escalation) and phase Ib (dose-optimization, dose-expansion). The study will last up to approximately 4 years.

Начало: 19.09.2024 Край: 01.10.2027 Възраст: от 18 г.

France, Germany, Japan +3 Eli Lilly and Company NCT06561685

1 … 49 50 51 52 53 … 100